subject: King Pharmaceuticals Inc.: Pharmavitae Profile - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Gain insight into Kings strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for King over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the companys prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Kings performance against key rivals in the prescription pharmaceutical sector
See how King, having suffered a period of declining sales, will return to positive growth over the forecast period
Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 200315 6
Operating costs and profit analysis 7
King Pharmaceuticals: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT Analysis 12
Chapter 3 Quarterly news update 20
Latest prescription pharma product news 20
Latest corporate news 21
Chapter 4 Company introduction 23
Key findings 23
Background 24
Key corporate developments 24
M&A history 25
Current corporate structure 27
Pharmaceuticals business unit structure 27
Chapter 5 Company sales 28
Key findings 28
Prescription pharmaceutical sales and growth rate analysis, 200315 29
Product analysis 31
Therapy area analysis 38
Geographic analysis 40
Launch/core/expiry analysis 42
Molecule type analysis 50
Externalization analysis 52
Chapter 6 Company financials 54
Key findings 54
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309 55
